GH Research PLC (GHRS) stock
GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.27−0.48 (-2.56%)
Close on Nov 17, 2026Market cap $1.13BP/E –Yield –
GH Research r&d expenses
Research and development expenses are spending on new products and technology.
GH Research's R&D Expenses for the twelve months ending Jun 30, 2026 was $46.73M, up 39.9% year over year. For fiscal 2025 it was $38.77M, up 10.7% from the year before. The highest annual figure on record is $38.77M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.77M | +10.7% |
| FY2024 | Dec 31, 2024 | $35.02M | +17.4% |
| FY2023 | Dec 31, 2023 | $29.82M | +45.6% |
| FY2022 | Dec 31, 2022 | $20.48M | +139.5% |
| FY2021 | Dec 31, 2021 | $8.55M | +2430.5% |
| FY2020 | Dec 31, 2020 | $338.00K | +14.2% |
| FY2019 | Dec 31, 2019 | $296.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.40M | +38.4% |
| Q1 FY2026 | Mar 31, 2026 | $12.38M | +57.7% |
| Q4 FY2025 | Dec 31, 2025 | $11.39M | +38.8% |
| Q3 FY2025 | Sep 30, 2025 | $10.57M | +25.8% |
| Q2 FY2025 | Jun 30, 2025 | $8.96M | -8.2% |
| Q1 FY2025 | Mar 31, 2025 | $7.85M | -9.3% |
| Q4 FY2024 | Dec 31, 2024 | $8.21M | -0.5% |
| Q3 FY2024 | Sep 30, 2024 | $8.40M | +18.5% |
| Q2 FY2024 | Jun 30, 2024 | $9.76M | +35.9% |
| Q1 FY2024 | Mar 31, 2024 | $8.66M | +18.5% |
| Q4 FY2023 | Dec 31, 2023 | $8.25M | +19.4% |
| Q3 FY2023 | Sep 30, 2023 | $7.09M | +53.4% |
| Q2 FY2023 | Jun 30, 2023 | $7.18M | +69.2% |
| Q1 FY2023 | Mar 31, 2023 | $7.31M | – |
| Q4 FY2022 | Dec 31, 2022 | $6.91M | – |
| Q3 FY2022 | Sep 30, 2022 | $4.62M | – |
| Q2 FY2022 | Jun 30, 2022 | $4.24M | – |
See a number that looks wrong?